We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

38 hedge funds and large institutions have $84.1M invested in Spyre Therapeutics in 2018 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

96% more capital invested

Capital invested by funds: $42.9M → $84.1M (+$41.2M)

23% more funds holding

Funds holding: 31 → 38 (+7)

0.12% more ownership

Funds ownership: 1.91% → 2.03% (+0.12%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
38
Holders Change
+7
Holders Change %
+22.58%
% of All Funds
0.87%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
16
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.81M
2
Jennison Associates
Jennison Associates
New York
+$807K
3
Renaissance Technologies
Renaissance Technologies
New York
+$505K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$478K
5
DZ Bank
DZ Bank
Germany
+$473K

Top Sellers

Rank Fund Capital Flow
1
DCM
DAFNA Capital Management
California
-$1.89M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$85K
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$72K
4
Macquarie Group
Macquarie Group
Australia
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$18.3M – – –
Jennison Associates
2
Jennison Associates
New York
$14.9M +$807K +4,466 +8%
O
3
OrbiMed
New York
$14.6M – – –
BBA
4
Baker Bros. Advisors
New York
$11.3M – – –
UOTTAIMCU
5
University of Texas/Texas AM Investment Management Co (UTIMCO)
Texas
$5.21M – – –
RSCM
6
Rock Springs Capital Management
Maryland
$5.2M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$3.35M +$478K +2,647 +24%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$2.48M +$1.81M +10,000 New
Renaissance Technologies
9
Renaissance Technologies
New York
$1.01M +$505K +2,796 +218%
BCM
10
Bridgeway Capital Management
Texas
$992K – – –
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$911K +$402K +2,227 +154%
Millennium Management
12
Millennium Management
New York
$736K +$436K +2,415 +437%
DZ Bank
13
DZ Bank
Germany
$649K +$473K +2,618 New
EI
14
EAM Investors
California
$563K +$410K +2,269 New
JP Morgan Chase
15
JP Morgan Chase
New York
$502K +$322K +1,784 +737%
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$307K +$150K +831 +206%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$304K – – –
Wells Fargo
18
Wells Fargo
California
$271K +$31.4K +174 +19%
William Blair & Company
19
William Blair & Company
Illinois
$270K +$116K +640 +143%
UBS Group
20
UBS Group
Switzerland
$244K +$168K +930 +1,755%
BlackRock
21
BlackRock
New York
$243K +$18.4K +102 +12%
LF
22
Lee Financial
Texas
$222K – – –
SIM
23
Spark Investment Management
New York
$188K +$56.4K +312 +70%
ARTA
24
A.R.T. Advisors
New York
$183K +$134K +739 New
Northern Trust
25
Northern Trust
Illinois
$181K +$12.8K +71 +11%
1
2

SYRE Hedge Fund Activity: Q1 2018 in Review

38 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2018, worth a combined $84.1M — up 96% from $42.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new SYRE positions and 4 closed out — a net gain of 7 holders — while 16 added to existing stakes and 0 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.81M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $1.89M sold.

  • 38 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2018, up from 31 in Q4 2017.
  • Funds reported $84.1M of Spyre Therapeutics stock for Q1 2018, up 96% quarter-over-quarter.
  • 11 funds opened new Spyre Therapeutics positions in Q1 2018 and 4 closed out, a net change of +7 holders.
  • The largest Spyre Therapeutics buyer in Q1 2018 was Adage Capital Partners, an estimated $1.81M added.
  • The largest Spyre Therapeutics seller in Q1 2018 was DAFNA Capital Management, an estimated $1.89M sold.

Based on aggregated 13F filings for Q1 2018.